291 related articles for article (PubMed ID: 20233398)
1. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
Lewis MG; Norelli S; Collins M; Barreca ML; Iraci N; Chirullo B; Yalley-Ogunro J; Greenhouse J; Titti F; Garaci E; Savarino A
Retrovirology; 2010 Mar; 7():21. PubMed ID: 20233398
[TBL] [Abstract][Full Text] [Related]
2. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
Shytaj IL; Norelli S; Chirullo B; Della Corte A; Collins M; Yalley-Ogunro J; Greenhouse J; Iraci N; Acosta EP; Barreca ML; Lewis MG; Savarino A
PLoS Pathog; 2012; 8(6):e1002774. PubMed ID: 22737073
[TBL] [Abstract][Full Text] [Related]
3. IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques.
Lugli E; Mueller YM; Lewis MG; Villinger F; Katsikis PD; Roederer M
Blood; 2011 Sep; 118(9):2520-9. PubMed ID: 21757617
[TBL] [Abstract][Full Text] [Related]
4. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
5. Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Del Prete GQ; Smedley J; Macallister R; Jones GS; Li B; Hattersley J; Zheng J; Piatak M; Keele BF; Hesselgesser J; Geleziunas R; Lifson JD
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):163-8. PubMed ID: 26150024
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Modulation of the Wnt/β-Catenin Pathway Inhibits Proliferation and Promotes Differentiation of Long-Lived Memory CD4
Mavigner M; Zanoni M; Tharp GK; Habib J; Mattingly CR; Lichterfeld M; Nega MT; Vanderford TH; Bosinger SE; Chahroudi A
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619550
[TBL] [Abstract][Full Text] [Related]
7. Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.
Murphey-Corb M; Rajakumar P; Michael H; Nyaundi J; Didier PJ; Reeve AB; Mitsuya H; Sarafianos SG; Parniak MA
Antimicrob Agents Chemother; 2012 Sep; 56(9):4707-12. PubMed ID: 22713337
[TBL] [Abstract][Full Text] [Related]
8. Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART).
Policicchio BB; Sette P; Xu C; Haret-Richter G; Dunsmore T; Pandrea I; Ribeiro RM; Apetrei C
PLoS One; 2018; 13(2):e0190908. PubMed ID: 29466356
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Intactness of Persistent Viral Genomes in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Initiating Antiretroviral Therapy within One Year of Infection.
Long S; Fennessey CM; Newman L; Reid C; O'Brien SP; Li Y; Del Prete GQ; Lifson JD; Gorelick RJ; Keele BF
J Virol; 2019 Dec; 94(1):. PubMed ID: 31597776
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status.
Villinger F; Brice GT; Mayne AE; Bostik P; Mori K; June CH; Ansari AA
Blood; 2002 Jan; 99(2):590-9. PubMed ID: 11781243
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
Rosenwirth B; ten Haaft P; Bogers WM; Nieuwenhuis IG; Niphuis H; Kuhn EM; Bischofberger N; Heeney JL; Uberla K
J Virol; 2000 Feb; 74(4):1704-11. PubMed ID: 10644340
[TBL] [Abstract][Full Text] [Related]
13. Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.
Kersh EN; Luo W; Adams DR; Mitchell J; Garcia-Lerma JG; Heneine W; Folks TM; Butera S; Otten RA
AIDS Res Hum Retroviruses; 2008 Apr; 24(4):543-6. PubMed ID: 18370590
[TBL] [Abstract][Full Text] [Related]
14. Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection.
Shytaj IL; Nickel G; Arts E; Farrell N; Biffoni M; Pal R; Chung HK; LaBranche C; Montefiori D; Vargas-Inchaustegui D; Robert-Guroff M; Lewis MG; Sacha JB; Palamara AT; Savarino A
J Virol; 2015 Aug; 89(15):7521-35. PubMed ID: 25972547
[TBL] [Abstract][Full Text] [Related]
15. Myeloid and CD4 T Cells Comprise the Latent Reservoir in Antiretroviral Therapy-Suppressed SIVmac251-Infected Macaques.
Abreu CM; Veenhuis RT; Avalos CR; Graham S; Parrilla DR; Ferreira EA; Queen SE; Shirk EN; Bullock BT; Li M; Metcalf Pate KA; Beck SE; Mangus LM; Mankowski JL; Mac Gabhann F; O'Connor SL; Gama L; Clements JE
mBio; 2019 Aug; 10(4):. PubMed ID: 31431552
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
Ortu F; Weimer LE; Floridia M; Manconi PE
Eur J Med Res; 2010 Feb; 15(2):81-3. PubMed ID: 20452889
[TBL] [Abstract][Full Text] [Related]
18. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.
Lifson JD; Piatak M; Cline AN; Rossio JL; Purcell J; Pandrea I; Bischofberger N; Blanchard J; Veazey RS
J Med Primatol; 2003 Aug; 32(4-5):201-10. PubMed ID: 14498980
[TBL] [Abstract][Full Text] [Related]
19. Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells.
Shen L; Shen Y; Huang D; Qiu L; Sehgal P; Du GZ; Miller MD; Letvin NL; Chen ZW
J Infect Dis; 2004 Oct; 190(8):1438-47. PubMed ID: 15378436
[TBL] [Abstract][Full Text] [Related]
20. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.
Parikh UM; Dobard C; Sharma S; Cong ME; Jia H; Martin A; Pau CP; Hanson DL; Guenthner P; Smith J; Kersh E; Garcia-Lerma JG; Novembre FJ; Otten R; Folks T; Heneine W
J Virol; 2009 Oct; 83(20):10358-65. PubMed ID: 19656878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
